Uniquity Bio is a clinical-stage drug development company focused on advancing scientific innovation and delivering novel medicines.
Uniquity Bio has raised $300.0M in total funding. The most recent round was Series A. The last funding was announced in May 2024.
Uniquity Bio's investors include Blackstone Life Sciences.
Uniquity Bio is headquartered in Malvern, United States.
Uniquity Bio is a clinical-stage drug development company focused on advancing scientific innovation and delivering novel medicines.
Uniquity Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Uniquity Bio — Funding & Investors." VCBacked, May 15, 2024, https://www.vcbacked.co/company/uniquity-bio. Accessed October 1, 2026.
VCBacked. (2024). Uniquity Bio — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/uniquity-bio
{{cite web |title=Uniquity Bio — Funding & Investors |url=https://www.vcbacked.co/company/uniquity-bio |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated